[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566936":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":29,"locations":34,"responsibleParty":96,"collaborators":20,"id":98,"slug":20,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":20,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":122,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"E-Scopics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Main cohort","EXPERIMENTAL","Patients recruited in the study will receive an ultrasound exam with Hepatoscope to collect quantitative measurements related to the severity of liver steatosis.",[13],"Device: Liver ultrasound",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Liver ultrasound","Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.",[9],null,[22,25],{"name":23,"affiliation":5,"role":24},"Claude Cohen-Bacrie","STUDY_DIRECTOR",{"name":26,"affiliation":27,"role":28},"Jerome Boursier, MD, PhD","University Hospital, Angers","STUDY_CHAIR",[30],{"name":26,"role":31,"phone":32,"phoneExt":20,"email":33},"CONTACT","+33 2 41 35 31 42","jeboursier@chu-angers.fr",[35,55,76],{"facility":36,"status":37,"city":38,"state":20,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University Hospital Angers","RECRUITING","Angers","49933","France",{"type":42,"coordinates":43},"Point",[44,45],-0.55202,47.47156,{"lat":45,"lon":44},[48,49,52],{"name":26,"role":31,"phone":32,"phoneExt":20,"email":33},{"name":50,"role":51,"phone":20,"phoneExt":20,"email":20},"Jerome Boursier, MD PhD","PRINCIPAL_INVESTIGATOR",{"name":53,"role":54,"phone":20,"phoneExt":20,"email":20},"Christophe Aubé, MD, PhD","SUB_INVESTIGATOR",{"facility":56,"status":37,"city":57,"state":20,"zip":58,"country":40,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Beaujon University Hospital","Clichy","92110",{"type":42,"coordinates":60},[61,62],2.30952,48.90018,{"lat":62,"lon":61},[65,69,70,72,74],{"name":66,"role":31,"phone":67,"phoneExt":20,"email":68},"Laurent Castera, MD, PhD","+33 1 40 87 55 24","laurent.castera@aphp.fr",{"name":66,"role":51,"phone":20,"phoneExt":20,"email":20},{"name":71,"role":54,"phone":20,"phoneExt":20,"email":20},"Valerie Vilgrain, MD, PhD",{"name":73,"role":54,"phone":20,"phoneExt":20,"email":20},"Marco Dioguardi Burgio, MD",{"name":75,"role":54,"phone":20,"phoneExt":20,"email":20},"Hélène Fontaine, MD",{"facility":77,"status":78,"city":79,"state":20,"zip":80,"country":40,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Pitie Salpetriere University Hospital","NOT_YET_RECRUITING","Paris","75013",{"type":42,"coordinates":82},[83,84],2.3488,48.85341,{"lat":84,"lon":83},[87,91,92,94],{"name":88,"role":31,"phone":89,"phoneExt":20,"email":90},"Raluca Pais, MD","+33 1 42 16 10 34","raluca.pais@aphp.fr",{"name":88,"role":51,"phone":20,"phoneExt":20,"email":20},{"name":93,"role":54,"phone":20,"phoneExt":20,"email":20},"Olivier Lucidarme, MD, PhD",{"name":95,"role":54,"phone":20,"phoneExt":20,"email":20},"Mathilde Wagner, MD, PhD",{"type":97,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100566936",false,"NCT06661655","Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD\u002FMASH Patients","ACOUSTIQ","Inclusion Criteria:\n\n* Adult patient below 80 yo\n* Patients with MASLD\u002FMASH recruited in interventional trials requiring MRI PDFF +\u002F- MRE per interventional protocol, OR\n* Patients with MASLD\u002FMASH recruited in prospective cohorts requiring MRI PDFF +\u002F- MRE per interventional protocol, OR\n* Patients referred to MRI-PDFF or MRE.\n* Patients who consented in written to participate in the study\n* Patients with ongoing social security coverage\n\nExclusion Criteria:\n\n* Patient in their minority (less than 18 yo) or older than 80 yo,\n* Patient with active implants,\n* Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant)\n* Patient with a history of decompensated cirrhosis,\n* Patient with a history of hepatocellular carcinoma,\n* Adult patient under tutorship, or unable to express informed consent,\n* Pregnant or breast-feeding\n* Person deprived from their liberty\n* Patient hospitalized without providing consent or in case of an emergency\n* Patient presenting with another know liver disease","ALL","18 Years","80 Years",{"count":108,"type":109},120,"ESTIMATED","INTERVENTIONAL",[112],"NA","The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.",[115,116,117,118,119,120,121],"Metabolic Syndrome X","Fatty Liver","MASH - Metabolic Dysfunction-Associated Steatohepatitis","MASLD","NASH (Non-Alcoholic Steatohepatitis)","Steatosis, Liver","NAFLD",[123,124,125,126,127,128,129,130,131,132],"Liver","Fibrosis","Steatosis","Elastography","Ultrasound","Attenuation","Backscattering coefficient","Sound speed","MRI PDFF","Hepatoscope","2025-08-12",{"date":135,"type":136},"2025-08-15","ACTUAL",{"date":138,"type":136},"2025-07-24",{"date":140,"type":109},"2026-09-01",{"name":5,"class":6},3]